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Abstract
We investigated whether imatinib (GleevecH, Novartis), a tyrosine kinase inhibitor, could improve functional outcome in
experimental spinal cord injury. Rats subjected to contusion spinal cord injury were treated orally with imatinib for 5 days
beginning 30 minutes after injury. We found that imatinib significantly enhanced blood-spinal cord-barrier integrity,
hindlimb locomotor function, sensorimotor integration, and bladder function, as well as attenuated astrogliosis and
deposition of chondroitin sulfate proteoglycans, and increased tissue preservation. These improvements were associated
with enhanced vascular integrity and reduced inflammation. Our results show that imatinib improves recovery in spinal cord
injury by preserving axons and other spinal cord tissue components. The rapid time course of these beneficial effects
suggests that the effects of imatinib are neuroprotective rather than neurorestorative. The positive effects on experimental
spinal cord injury, obtained by oral delivery of a clinically used drug, makes imatinib an interesting candidate drug for
clinical trials in spinal cord injury.
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Introduction
Traumatic injury to the spinal cord results in irreversible
locomotor, sensory, and autonomic dysfunctions for which there is
currently no effective pharmacologic treatment. The functional
losses are due not only to the initial physical disruption of spinal
cord tissue and vascular changes, but also to a cascade of
secondary events triggered by the initial insult, which results in
further damage to the spinal cord at and around the site of injury
[1]. These detrimental secondary events include the loss of
microcirculation, edema, hemorrhage, and local inflammation
[2,3], [3,4]. Incomplete understanding of how these events evolve
and contribute to pathology has been a major impediment to the
development of treatments for spinal cord injury.
Imatinib (GleevecH, Novartis) is a tyrosine kinase inhibitor used
clinically to treat Bcr/Abl-expressing leukemias and c-Kit-
expressing gastrointestinal stromal tumors. Experimentally, im-
atinib has been reported to modulate tyrosine kinase signaling
cascades involved in local inflammation, such as c-Kit, c-Fms, and
LCK [5], [6]. Imatinib-induced inhibition of c-Kit and c-Fms
activation has been reported to inhibit cytokine production in mast
cells and macrophages, respectively [5], while inhibition of LCK
has been reported to modulate the cytokine production/secretion
profile in effector T cells [7]. Imatinib has also been reported to
inhibit PDGF signaling [8], [9], [10] and, in an experimental
model of ischemic stroke, to reduce edema and hemorrhage [8],
[11]. In the stroke model, evidence was obtained for a mechanism
involving normalization of the blood-brain barrier by imatinib-
induced inhibition of PDGFR-a signaling on perivascular
astrocytes [8].
Since imatinib has previously been shown to reduce hemor-
rhage, edema, and inflammation, which are all considered
detrimental to functional outcome in spinal cord injury [12],
[13], [14], [15], [16], [17], [18], [19], we investigated the effects of
imatinib on functional and histological outcome in a clinically
relevant experimental model of spinal cord injury in rats. We
found that an oral, 5-day treatment course with imatinib
significantly enhanced hind limb locomotor function, bladder
function, and sensorimotor integration. We also found that
imatinib significantly enhanced tissue preservation and reduced
inflammation, astrogliosis, and chondroitin sulfate proteoglycan
deposition. Furthermore, we found evidence in support of the
potential of imatinib to normalize vascular integrity in the injured
spinal cord. Our results provide evidence in support of the
therapeutic potential of imatinib as a possible treatment for spinal
cord injury.
Results
Imatinib Enhances Functional Outcome
We investigated the effects of a 5-day treatment course with
either imatinib (250 mg/kg/day orally) or PBS beginning 30
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subjected to a contusion injury to the spinal cord (25 mm weight
drop). Assessment of hindlimb function revealed significantly
enhanced locomotor function. By day 56 post-injury, 70% of
imatinib-treated rats had regained the ability to make uncoordi-
nated weight-supported steps (mean 6 SD: 10.361.6; N=10;
Fig. 1 A, Fig. S1), while PBS-treated rats only regained the ability
to extensively move all three hindlimb joints (mean 6 SD:
7.161.43; N=10; Fig. 1 A, Fig. S1). Using the contact plantar
placement test, we found that sensorimotor integration was
significantly better with imatinib (mean 6 SD: 4.761.33;
N=10) than PBS (mean 6 SD: 2.261.9; N=10) by day 56
post-injury (Fig. 1 B, Fig. S1). Assessment of bladder function
revealed that imatinib significantly reduced peak residual urine
volumes (mean 6 SD: 4.2560.85 ml; N=10) compared to PBS
(mean 6 SD: 7.061.29 ml; N=10) and expedited restoration of
voiding function (Fig. 1 C, Fig. S1). By day 21 post-injury,
0.1560.33 ml of urine (mean 6 SD) was collected from imatinib-
treated rats compared to 1.260.85 ml of urine (mean 6 SD) from
PBS-treated rats. This effect was not due to altered fluid intake,
since fluid consumption did not differ between imatinib and PBS
treated groups (Data not shown). In addition, imatinib treatment
was associated with less injury-induced weight-loss than PBS
treatment (imatinib, N=10; PBS, N=10; Fig. S2).
Imatinib Enhances Tissue Preservation
Imatinib led to significantly more preserved tissue at the injury
site, as well as in spinal segments caudal to the injury, as compared
to PBS-treated rats when assessed at day 56 post-injury (imatinib,
N=7; PBS, N=7; Fig. 2 A, C); and imatinib was associated with
increased myelin volume (2.01060.49%, N=7) compared to PBS
(1.41360.43%, N=7; p=0.0504, Fig. S3). Imatinib also signif-
icantly reduced spinal cyst volumes caudal to the injury (imatinib,
N=7; PBS, N=7; Fig. 2 A, C). Importantly, imatinib was
associated with a significant increase in the area of neurofilament
immunoreactive axons within the white matter of the injury site
(mean 6 SD: 5.362.95%) compared to PBS treatment (mean 6
SD: 1.060.29%), as well as in spinal segments 7 and 14 mm
rostral and caudal to the injury (imatinib, N=7; PBS, N=7; Fig. 2
B, D, E).
Imatinib Treatment Modulates the Inflammatory
Response
We assessed plasma concentration of IL-1b, IL-6, IL-8, and
TNF-a, cytokines known to elicit the acute phase response, and
found that imatinib had no significant impact on any of these
cytokines at 6 hours and 5 days post-injury (imatinib, N=4; PBS,
N=4; Fig. 3). Imatinib did lead to a significant increase in plasma
levels of TNF-a compared to PBS (38.1867.2 pg/ml vs.
6.5363.9 pg/ml) at 3 days post-injury (p,0.001; Fig. 3). We next
assessed the effects of imatinib on neutrophil infiltration into the
injury site 24 hours after injury using MPO immnoreactivity and
found that imatinib did not significantly alter MPO immunore-
activity (imatinib, N=4; PBS, N=4; Fig. 4 A, B).
CD68 immunoreactivity was used to detect activated microglia/
macrophages at day 5 post-injury to assess the impact of the 5-day
treatment course on inflammation. We found that imatinib
treatment significantly reduced the areas of CD68 immunoreac-
tive activated macrophages/microglia within the injury site (mean
6 SD: 3.5661.88%) as compared to PBS treatment (mean 6 SD:
12.0566.34%), as well as in spinal segments around the injury
(imatinib, N=4; PBS, N=4; Fig. 3 C, D). Imatinib treatment was
also associated with significantly reduced CD68 immunoreactivity
at day 56 post-injury within the injury site (mean 6 SD:
12.0763.15) compared to PBS treatment (mean 6 SD:
23.0965.09%; imatinib, N=7; PBS, N=7; Fig. 3 E, F). We next
co-labeled CD68 positive cells with the proliferation marker Ki67,
and found that imatinib had no significant impact on proliferation
Figure 1. Imatinib enhances functional outcome. (A) Hindlimb
locomotor function assessed by the BBB locomotor rating scale. The red
line indicates BBB score 9, when weight-support begins. Scores above 9
represent walking, while scores below 9 represent no walking. (B)
Contact plantar placement (CPP) test of sensorimotor function. (C)
Bladder residual urine volumes. Imatinib (N=10) compared to PBS
(N=10). Data presented as mean 6 SEM: *P,0.05, **P,0.01, and
***P,0.001.
doi:10.1371/journal.pone.0038760.g001
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N=4; PBS, N=4; Table 1; Fig. S4). We also investigated whether
imatinib affected the proliferation of leukocytes expressing CD11b,
and found that there was no significant effect (imatinib, N=4;
PBS, N=4; Table 1; Fig. S4). Co-localization of CD68 at day 7
post-injury with either PDGFR-a or NG2 revealed that CD68
immunoreactive cells did not co-localize with either marker (Fig.
S5). We did, however, find a small population of CD11b
immunoreactive cells that were co-localized with NG2 (Fig. S4).
Imatinib Attenuates Astrocyte Reactivity and Chondroitin
Sulfate Proteoglycan Deposition
Imatinib was associated with less intense GFAP immunoreac-
tivity than PBS at day 5 (imatinib, N=4; PBS, N=4; Fig. 5 A).
While GFAP intensity increased between days 5 and 56, it
remained less intense in imatinib-treated, compared to PBS-
treated rats (imatinib, N=7; PBS, N=7; Fig. 5 A) also 56 days
after injury. To study chondroitin sulphate proteoglycans, we used
CS56 and NG2 antibodies and found that imatinib significantly
reduced the area of CS56 and NG2 immunoreactivity within the
injury site and in spinal segments 7 and 14 mm rostral and caudal
to the injury at day 5 post-injury (imatinib, N=4; PBS, N=4;
Fig. 5 B-E, Fig. S6). CS56 and NG2 immunoreactivities within the
Figure 2. Imatinib enhances tissue preservation. H&E staining was used to visualize tissue and spinal cysts within the epicenter and in spinal
segments 7 and 14 mm rostral and caudal to the injury. (A) Representative micrographs of tissue preservation and spinal cysts at day 56 post-injury in
the injury site and in spinal segments 7 mm rostral and caudal to the injury. Arrows indicate spinal cysts. Asterisk indicates possible enlargement of
the central canal. (B) Representative micrographs of NF immunoreactivity within the injury site at day 56 post-injury. (C) Quantification of tissue
preservation and spinal cyst volumes within the injury site and 7 mm caudal to the epicenter at day 56 post-injury (imatinib n=10; PBS n=10). (D)
Quantification of NF immunoreactivity within the injury site and in spinal segments 7 and 14 mm rostral and caudal to the injury at day 56 post-
injury. (E) Scatter plot of NF immunoreativity within the injury site. Imatinib (N=7) compared to PBS (N=7). Data presented as mean 6 SD: *P,0.05,
**P,0.01, and ***P,0.001. Scale bars: (A) 1 mm, (B) 100 mm.
doi:10.1371/journal.pone.0038760.g002
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spinal cords of imatinib-treated rats and 4.9361.12 and
13.3362.09 in the spinal cords of PBS-treated rats. As NG2 is
also a marker for progenitor cells capable of differentiating into
oligodendrocytes and astrocytes, we quantified the effect of
imatinib on the proliferation of NG2 immunoreactive cells by
double labeling with Ki-67. We found that imatinib significantly
reduced the percentage of NG2/Ki-67double-labeled cells 7 mm
caudal to the injury, with 17.9613.7% proliferating NG2 positive
cells in the spinal cords of imatinib-treated rats compared to
50.7611.7% proliferating NG2 positive cells in the spinal cords of
PBS-treated rats (imatinib, N=4; PBS, N=4; Table 1; Fig. S4).
Imatinib Enhances Blood-spinal Cord-barrier Integrity
To determine the effects of imatinib on blood-spinal cord-
barrier (BSCB) integrity, we evaluated the expression of claudin-5,
an endothelial cell tight junction protein at day 5 after injury. We
found more intense claudin-5 immunoreactivity within the dorsal
horns of imatinib-treated rats compared to PBS-treated rats
(imatinib, N=4; PBS, N=4; Fig. 6 A). We also observed that
imatinib caused pericytes, as identified by PDGFR-b immunore-
activity, to remain confined to the vascular walls after injury, thus
resembling the distribution of PDGFR-b expressing cells in non-
injured tissue. In contrast, spinal cord injury caused PDGFR-b
immunoreactive cells to expand their territory away from the
blood vessels in PBS-treated rats (imatinib, N=4; PBS, N=4;
Fig. 6 B).
To assess BSCB integrity, we quantified leakage of two proteins,
albumin and IgG, which are normally contained within the
circulation but leak into parenchyma following CNS injury. At day
5 post-injury, we found that imatinib significantly reduced leakage
of both proteins into the injury site (1.4460.56 and 1.1260.65,
respectively) compared to PBS treatment (11.2369.8% and
8.8665.43%, respectively). Imatinib also significantly reduced
albumin leakage into spinal cord segments rostral and caudal to
the injury and reduced IgG leakage in spinal segments caudal to
the injury (imatinib, N=4; PBS, N=4; Fig. 6 C-H). Furthermore,
early signs of better tissue morphology were observed in the spinal
cord of imatinib-treated rats at day 5 post-injury (Fig. 6 I).
Imatinib Reduces Expansion and Proliferation of PDGFR
Expressing Cells
In the uninjured spinal cord, PDGFR-a is expressed on
perivascular astrocytic endfeet (N=3; Fig. S7), while PDGFR-b
is expressed on pericytes. Spinal cord injury induced a rapid
increase of both PDGFR-a and PDGFR-b expression, evident 24
hours after injury (sham, N=2; injured, N=2; Fig. S7). At day 5
post-injury, we observed a significant reduction in PDGFR-a
immunoreactivity within the dorsal column at the injury site and
7 mm rostral to the injury in the spinal cords of imatinib-treated
(2.5360.06) rats when compared to the spinal cords of PBS-
treated rats (4.5961.14; imatinib, N=4; PBS, N=4; Fig. 7 A).
Similarly, we observed a significant reduction in PDGFR-b
immunoreactivity within the dorsal column of imatinib-treated
vs PBS-treated rats, 1.9560.64% and 3.1861.33% respectively
(imatinib, N=4; PBS, N=4; Fig. 7 B). We also investigated
whether PDGFRs were expressed constitutively on neurons as
previously reported [20] and found that PDGFRs were neither
constitutively expressed nor induced by injury in neurons in the rat
spinal cord (sham, N=2; injured, N=2; Fig. S8).
Co-labeling with the proliferation marker, Ki67, revealed that
only a small population of PDGFR-a and PDGFR-b immunore-
active cells were proliferating within the injury site and 7 mm
caudal to the injury at day 5 post-injury (imatinib, N=4; PBS,
Figure 3. Impact of imatinib on plasma concentrations of pro-inflammatory cytokines. (A) IL-1b plasma concentrations. (B) IL-6 plasma
concentrations. (C) IL-8 plasma concentrations. (D). TNF-a plasma concentrations. Imatinib (N=4) compared to PBS (N=4). Data presented as the
mean 6 SD. ***P,0.001.
doi:10.1371/journal.pone.0038760.g003
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reduction of the small number of proliferating PDGFR-b
immunoreactive cells within the injury site (1.663.1 vs 8.162.7
for imatinib and PBS respectively). Imatinib had no effect on the
proliferation of PDGFR-a immunoreactive cells within the injury
site or 7 mm caudal to the injury at day 5 post-injury.
Discussion
We found that an oral, 5-day treatment with imatinib
significantly enhanced functional outcome after experimental
contusion spinal cord injury of the spinal cord. Imatinib-treated
rats regained the ability to make weight-supported steps with their
hind limbs, which was in stark contrast to PBS-treated rats that
only regained the ability to make rhythmic sweeping motions with
their hind limbs. Imatinib-treated rats also regained significantly
greater sensorimotor integration than PBS-treated rats. Injury-
induced bladder dysfunction was restored by imatinib, and injury-
induced weight loss was reduced in imatinib-treated rats. The
restoration of bladder function obtained with imatinib is of
particular clinical relevance for quality of life, since restoration of
bladder function is consistently ranked as a higher priority than
walking for both quadriplegics and paraplegics [21].
Currently, high dose methylprednisolone administered within 8
hours of injury is the only clinically used pharmacologic
intervention for spinal cord injury. Controversy regarding its
efficacy has led clinics to abandon its use [22], so there is need for
alternative pharmacologic interventions for the treatment of spinal
Figure 4. Imatinib attenuates acute and chronic inflammation. Effects of 30 minute delayed imatinib treatment on MPO immunoreactive
neutrophils within the injury site at 24 hours post-injury and CD68 immunoreactive activated macrophages/microglia at day 5 post-injury. (A)
Representative micrographs of MPO immunoreactivity at 24 hours post-injury. (B) Quantification of MPO immunoreactivity within the injury site at 24
hours post-injury (imatinib, N=4; PBS, N=4). (C) Representative micrographs of CD68 immunoreactivity at day 5 post-injury. (D) Quantification of
CD68 immunoreactivity within the spinal cord at day 5 post-injury (imatinib, N=4; PBS, N=4). (E) Representative micrographs of CD68
immunoreactivity for activated macrophages/microglia within the injury site 14 mm caudal of the epicenter at day 56 post-injury. (F) Quantification
of the relative area occupied by CD68 immunoreactivity within the injury site and in spinal segments 7 and 14 mm rostral and caudal to the injury at
day 56 post-injury (imatinib, N=6; PBS, N=6). Data presented as mean 6 SD: *P,0.05, **P,0.01, and ***P,0.001. Scale bars: 100 mm, inset: 10 mm.
doi:10.1371/journal.pone.0038760.g004
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outcome presented here indicate that imatinib may potentially fill
this need.
The beneficial effects of imatinib on functional outcome may in
part be due to increased tissue preservation within the injury site,
since the amount of preserved tissue has previously been positively
correlated with functional outcome [23]. In particular, the
significantly larger amount of NF-reactive axons traversing the
injury site may have also contributed to the functional effects, since
the number of axons (protected and/or regenerated) traversing the
epicenter is arguably the single most important histological
indication of degree of function. Imatinib also counteracted other
indices of tissue pathology, such as astrogliosis and CSPG
deposition, which is presumably valuable because both the
astroglial scar and CSPGs are considered detrimental to axon
regeneration and functional outcome [24], [25], [26].
The expansion of NG2 immunoreactive progenitor cells, which
differentiate into both astrocytes and oligodendrocytes in response
to injury [27], was significantly reduced by imatinib. This
observation is significant in that NG2 cells have been reported
to proliferate in response to demyelination [28], [29], and the time
course of NG2 cell proliferation has been reported to parallel the
time of demyelination and remyelination in the spinal cord [30]. It
is also important to mention that little to no activated
macrophages/microglia and very few non-activated macrophag-
es/microglia expressed this marker, so the effects of imatinib on
NG2 immunoreactive cells does not reflect an effect on the
subpopulations of macrophages/microglia that have been report-
ed to express this marker [31], [32]. Thus, it is plausible that the
imatinib-induced reduction of NG2 cell proliferation reflects
decreased tissue damage and the observed reduction in the
amount of reactive astrocytes.
Imatinib has been reported to inhibit multiple receptor tyrosine
kinases in mast cells, macrophages, and T-lymphocytes, as well as
PDGFR-a and b [5], [33], [34]. We observed a significant
reduction in amounts of activated macrophages/microglia in the
spinal cords of imatinib-treated rats, which is noteworthy because
depletion of hematogenous macrophages and attenuation of T-
lymphocytes, potent activators of macrophages, have both been
reported to enhance tissue preservation in experimental spinal
cord injury [35], [36]. Moreover, blockade of a4b1 integrin has
been reported to limit secondary inflammatory damage after
spinal cord injury [37], [38], [39] Imatinib has also been shown to
abrogate macrophage activation and cytokine production in an
experimental arthritis model [5]. Under the current experimental
conditions, imatinib had no significant effect on ED-1 immuno-
reactive macrophage proliferation; however, we cannot rule out
that imatinib had an effect on activation state or cytokine
production.
We observed that imatinib markedly reduced the expansion of
PDGFR-a and PDGFR-b expressing cell populations, with the
strongest reductions being seen in the areas of the greatest tissue
preservation. Astrocytes and O2A progenitors, as well as pericytes
expressing PDGFR-a and PDGFR-b, respectively, are sources of
CSPGs [40], [41]. Thus, we have observed not only a marked
reduction in CSPG, but also a marked reduction of cellular sources
of CSGP. Although it has been reported that PDGFR-a is
expressed on neurons in primary neuronal cultures [20], PDGFR-
a was neither constitutively expressed nor induced by injury in
neurons in the rodent spinal cord, indicating that PDGFR-a
inhibition is not having a direct effect on neurons. It has also been
reported that a subset of activated macrophages/microglia express
PDGFR-a [42]; however, under the current experimental
condition, ED-1 immunoreactive activated macrophages/microg-
lia did not express PDGFR-a. Thus, the effects of imatinib on
PDGFR-a do not constitute an effect of imatinib on the
subpopulation of activated macrophages/microglia that express
PDGFR-a.
We found that imatinib increased immunolabeling of the
endothelial tight junction protein, claudin-5, and that PDGFR-b
immunoreactive pericytes remained located tightly around vessel
walls in a pattern similar to that seen in non-injured rats, thus
indicating normalization of the blood-spinal cord-barrier. In the
absence of imatinib, injury caused a spreading of PDGFR-b
immunoreactive cells away from vessel walls. This observation is in
accordance with a previous report that pericytes migrate away
from the neurovascular unit in response to CNS injury [43]. The
effects of imatinib on BSCB integrity are in agreement with the
effects found in a mouse model of ischemic stroke, where imatinib
promotes BBB integrity and reduces stroke volume by inhibiting
PDGF-CC induced activation of PDGFR-a on perivascular
astrocytic endfeet [8].
Given that imatinib has been reported to modulate immune cell
function and secretion profile, it was surprising to observe that
imatinib treatment had no significant impact on plasma concen-
trations of pro-inflammatory cytokines, IL-b, IL-6, IL-8, and
TNF-a, reported to be involved in the orchestration of the
inflammatory response [44], [39], [37] at 6 hours post-injury
which translates to 5.5 hours after the treatment began. It was also
surprising to find that imatinib had no impact on neutrophil
infiltration into the injured spinal cord 24 hours after injury.
Collectively, these results indicate that imatinib has no significant
impact on the generation of the innate immune response and that
the immune response between the treatment groups immediately
after injury were similar.
Remarkably, imatinib treatment associated with increased
plasma concentrations of TNF-a, an inflammatory cytokine
produced primarily by macrophages and reported to induce
inflammation [45], at day 3 post-injury. This was followed by
significantly reduced areas of activated macrophage/microglia
expression at day 5 post-injury, an unexpected finding since
macrophages filtration has been reported to peak between 5 to 7
days [46]. One possible explanation for the lack of accordance
between the plasma correlate of inflammation and tissue
inflammation could be that of normalization of BSCB integrity
in the spinal cords of rats treated with imatinib prevented
macrophage infiltration into the injured spinal cord. Indeed, it has
previously been reported that imatinib normalizes the integrity of
the BBB and reduces infarct volume in a murine model of
ischemia stroke [8]. Continued research is necessary to determine
Table 1. Proportion (%) of proliferating cells co-expressing
CD68, CD11b, PDGFRs or NG2 at the injury site and 7 mm
caudal to the injury.
Injury site 7 mm caudal to injury
PBS imatinib PBS imatinib
CD68 8.763.2 8.865.4 13.367.9 10.4610.0
CD11b 36.465.2 31.267.8 42.968.6 4865.3
PDGFR-a 13.469.6 20.868.9 10.867.8 23.3611.8
PDGFR-b 8.162.7 1.663.1* 2.162.4 0
NG2 50.469.4 45.064.1 50.7611.7 17.9613.7*
Data presented as mean 6 SD: *P,0.05.
doi:10.1371/journal.pone.0038760.t001
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cells, since inhibition/modulation of the secretion profile of
immune cells could theoretically result in reduced permeability
of the BSCB and normalization of blood vessels, while normal-
ization of the BSCB by inhibiting immune cells from entering the
spinal cord.
In conclusion, we present robust evidence in support of a new
indication for imatinib as an acute treatment for spinal cord injury.
The rapid time course of the beneficial effects and the fact that a 5-
day treatment period leads to lasting improvements of both
structure and function, suggest that imatinib is neuroprotective
rather than neurorestorative. A specific advantage of imatinib is
that it is currently in clinical use for other indications, offering a
putative off the shelf therapy with fewer hurdles en route to clinical
trials.
Materials and Methods
Ethics Statement
Animal work was approved by the North Stockholm Animal
Ethics Committee (permit # N429/09). Animals received
analgesic pre-operative, for 3 days post-injury to alleviate pain,
and as needed thereafter. Antibiotics were given for 7 days post-
injury to prevent bladder infection. Bladders were manually
expressed twice/day until bladder function was restored. Animals
were communally housed and had access to food/water at will.
Figure 5. Imatinib attenuates astrogliosis and CSPG deposition. (A) Representative micrographs of dorsomedial GFAP immunoreactivity
14 mm caudal to the injury site at 5 and 56 days post-injury. (B) Representative micrographs of CS56 immunoreactivity within the injury site at day 5
post-injury. (C) Quantification of CS56 immunoreactivity within the injury site and spinal segments 7 and 14 mm rostral and caudal to the injury at
day 5. (D) Representative micrographs of NG2 immunoreactivity within the injury site at day 5 post-injury. (E) Quantification of NG2 immunoreactivity
within the injury site and in spinal segments 7 to 14 mm rostral and caudal to the injury site at day 5. Imatinib (day 5, N=4; day 56, N=6) compared
to PBS (day 5, N=4; day 56, N=6). Data presented as mean 6 SD: *P,0.05, **P,0.01, and ***P,0.001. Scale bars: 100 mm.
doi:10.1371/journal.pone.0038760.g005
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38760Figure 6. Imatinib enhances vascular integrity. (A) Tight junction protein, claudin-5, immunoreactivity in endothelial cells in the dorsal horn at
5 days post-injury is stronger in imatinib than in PBS-treated rats. This indicates better preservation of the BSCB integrity. (B) Representative
micrographs of PDGFR-b/lectin immunoreactivity at day 5 post-injury in the spinal cords of non-injured, PBS-treated, and imatinib-treated rats.
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Under deep anesthesia (Isofluorane), a laminectomy was
performed at T10 and the caudal half of T9, and a 10 g weight
was dropped from a height of 25 mm (220 g, Scanbur, Sweden)
onto the dorsal surface of the spinal cord using the Impactor (Keck
Center for Neurosciences) in female rats. The rats were randomly
divided into 2 treatment groups, imatinib (N=18) or PBS (N=18).
250 mg/kg/day of imatinib was administered orally 30 minutes
after injury and twice daily thereafter for 5 days. In sham operated
rats (N=5), only the laminectomy was performed. In addition,
injured untreated animals (N=2) were included and sacrificed at
day 5 post-injury.
Post-operatively, an antibiotic (Borgal, Hoechst, AG) was
administered once/daily for 7 days to prevent urinary tract
infection, and an analgesic (Temgesic, Schering-Plough, AB) was
administered twice/day for 3 days. Bladders were manually
expressed twice daily for the first 7 days post-injury and once/day
thereafter until bladder function was restored. Residual urine was
collected and the volumes recorded for 21 days post-injury.
Weights were recorded before injury, day 3 post-injury, and
weekly thereafter. Food and water was provided ad libitum, and
animals were housed 4/cage in a room with a 12-hour light/dark
cycle.
For all of the following experimental procedures, the experi-
menters were blinded to the treatment groups during the
behavioral testing as well as during the histological analysis. To
ensure unbiased evaluation, the following steps were taken: one
surgeon performed all surgeries, a surgical assistant randomly
assigned animals to treatment groups and assigned ID numbers to
the rats, and experimenters involved in behavioral experiments did
not treat the animals–so they did not know which animals
belonged to which treatment group. For histology, the animals
were given different ID numbers and the spinal cords of 3 different
animals were placed on the same slide. Once staining/IHC
analysis was completed, the code was broken and statistical
analysis was performed.
Locomotor Evaluation
The Basso, Beattie, Bresnahan (BBB) locomotor rating scale
[23] was used to evaluate hind limb locomotor function in an open
field weekly for 8 weeks. All experimenters involved with BBB
evaluation were blinded to treatment group identity.
(C) Representative micrographs of albumin immunoreactivity within the injury site at day 5 post-injury. (D) Representative micrographs of IgG
immunoreactivity within the injury site at day 5 post-injury. (E) Quantification of albumin immunoreactivity within the spinal cord at day 5 post-injury.
(F) Quantification of IgG immunoreactivity within the spinal cord at day 5 post-injury. (G) Scatter plot of the area of albumin immunoreactivity within
the injury site at day 5 post-injury. (H) Scatter plot of the area of IgG immunoreactivity within the injury site at day 5 post-injury. (I) H and E staining of
the spinal cord at day 5 post-injury. Circles indicate areas without H and E staining. Imatinib (day 5, N=4) compared to PBS (day 5, N=4). Data
presented as mean 6 SD: *P,0.05, **P,0.01, and ***P,0.001. Scale bars: (A,C,E) 100 mm,(G,I) 1 mm, (B)1 0mm.
doi:10.1371/journal.pone.0038760.g006
Figure 7. Effects of 30 minute delayed, 5-day imatinib treatment on PDGFR expression at day 5 after contusion spinal cord injury.
(A) Representative micrographs of PDGFR-a immunoreactivity within the injury site and quantification of PDGFR-a immunoreactivity within the injury
site and in spinal segments rostral and caudal to the injury in non-injured, PBS-treated, and imatinib-treated rats. (B) Representative micrographso f
PDGFR-b expression within the injury site and quantification of PDGFR-b expression within the injury site and spinal segments rostral and caudal to
the injury in non-injured, PBS-treated, and imatinib-treated rats. Imatinib (N=4) compared to PBS (N=4). Data presented as mean 6 SD: *P,0.05.
Scale bars: 100 mm.
doi:10.1371/journal.pone.0038760.g007
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The contact plantar placement test was used to assess
sensorimotor integration weekly, beginning 1 week post-injury.
Briefly, the dorsal surface of each hind paw was lightly touched
against the edge of a standard laboratory bench, and the ability of
the rat to make plantar contact with the bench was scored by the
number of times this response was elicited during three trials for
each hind limb individually (max. score =6). Data presented as
the sum of left and right responses. All experimenters involved
with BBB evaluation were blinded to treatment group identity.
Immunohistochemistry, Hematoxylin and Eosin, and
Luxol Fast Blue Staining
Albumin (Abcam), biotinylated anti-rat IgG antibodies (Santa
Cruz Biotechnology), fibronectin (Abcam), and claudin-5 (Zymed)
antibodies were used to evaluate vascular permeability and BSCB
integrity [47,48]. Antibodies to CD68 or CD11b (AbD Serotec)
were used to evaluate activated and non-activated macrophages/
microglia, respectively. GFAP antibodies (Dako and Sigma-
Aldrich) were used to evaluate astrocyte reactivity. Ki67 antibodies
(Pharmingen and Novocastra) were used to evaluate cell prolifer-
ation. PDGFR-a (Cell Signaling), PDGFR-b (Cell Signaling), and
NG2 (Chemicon) antibodies were used to visualize astrocytes,
pericytes, and progenitor cells, respectively. CS-56 antibodies
(Sigma) were used to evaluate CSPG deposition. Neurofilament
antibodies (SMI-312, Abcam) were used to evaluate axon sparing
in white matter. MPO antibodies (Bio Site) were used to evaluate
neutrophil infiltration into the injured spinal cord. Biotinylated
lycopersicon esculentum (tomato) lectin (Vector Laboratories) and
occludin-1 (Zymed) or podocalyxin (R&D Systems) antibodies
were used as endothelial cell markers. NeuN antibodies (Chemi-
con) were used as neuronal markers. DAPI (Invitrogen) was used
to identify nuclei. For PDGFR-a and -b immunolabeling, antigen
retrieval for 15 minutes at 95uC with high pH retrieval buffer
(Dako) was required. Sections were incubated for 1 hour at room
temperature with either Alexa fluorophores (Molecular Probes) or
Cy3-labeled avidin. Bound antibodies were visualized using
epifluorescence microscopy (Nikon Eclipse1000) and photo-
graphed (Spot camera, Spot Advance software, Tekno optik), or
visualized and photographed using confocal microscopy (Zeiss 710
and LSM software).
For Hematoxylin and Eosin staining, cryosections were stained
with Mayer’s hematoxylin. Thereafter, sections were incubated in
0.2% eosin solution (Histolab). For luxol fast blue staining,
cryosections were stained with luxol fast blue solution (Sigma
Aldrich).
ELISA
Cytokines (IL-1b, IL-6, IL-8, TNF-a) in the supernatant was
analyzed using a 9-plex ultra-sensitive elisa kit from Mesoscale
(Mesoscale, Gaithersburg, Maryland). After blocking with BSA for
30 minutes the supernatant was added to the plate and incubated
overnight at 4uC. After washing, the plate was incubated with
MSD-SULFO-TAG labeled secondary antibody for 2 hours,
washed, and analyzed using a Mesoscale plate reader.
Transgenic Mice
PDGFRa
+/GFP mice on C57BL/6J genetic background were
perfused with 4% PFA/PBS under deep Hypnorm/Dormicum
anesthesia.
Stereology
Unbiased stereology was used to determine the volumes spared
tissue and spinal cysts in a 7 mm segment centered on the injury
site and a 7 mm segment immediately caudal to the injury
segment stained with Hematoxylin and Eosin. We also used
unbiased stereology to quantify the volume of spared myelin
within the injury site in sections stained with luxol fast blue. With
both stains, a total of 9 sections were analyzed per animal for each
of the spinal segments. Stereological analysis was based on the
Cavalieri Principle (Stereologer, SPA Inc., MD) using the three
dimensional optical dissector [49]. Results are reported as mean
volume 6 SEM.
Statistical Evaluation
For comparisons of BBB scores, residual urine volumes, CPP
scores, tissue preservation volumes, and weight gain, Repeated
measures ANOVA was performed with Bonferroni post-hoc test.
The confidence interval was set at 95%. Data are presented as
mean 6 SEM, with P-values ,0.05 considered significant.
For immunofluorescence, patterns were photographed; and
from each animal, 3 micrographs/spinal cord segment were taken
for each animal of each spinal cord regions assessed. The
micrographs were analyzed using ImageJ (NIH). The proportions
of stained area/total area were compared between treatment
groups. The proportion of proliferating cells was evaluated from
co-immunolabeled sections by manual counting. Data are
presented as mean 6 SD and P-values were obtained using
Student’s t-test. P-values ,0.05 were considered significant.
Supporting Information
Figure S1 Scatter plot representation of functional
outcome at day 56 post-injury. Hindlimb locomotor function
assessed by the BBB locomotor rating scale. The red line indicates
BBB score 9, when weight-support begins. Scores above 9
represent walking, while scores below 9 represent no walking.
(B) Contact plantar placement (CPP) test of sensorimotor function.
(C) Bladder residual urine volumes. Imatinib (N=10) compared to
PBS (N=10). Data presented as the mean 6 SD.
(TIF)
Figure S2 Effects of 30 minute delayed treatment on
injury-induced weight loss. Results from a repeated measures
ANOVA revealed that imatinib had significant treatment
(P,0.001) and time effects (P,0.001; imatinib, N=10; PBS,
N=10). Data presented as the mean 6 SEM. 0= day of spinal
cord injury.
(TIF)
Figure S3 Myelin preservation. Representative micrographs
of luxol fast blue staining within in the injury site at day 56 post-
injury in the spinal cords of (A) PBS treated rats. (B) imatinib
treated rats. (C) Quantification of the volume of luxol fast blue
stained tissue within the injury site at day 56 post-injury
(p=0.0504; imatinib, N=6; PBS, N=6). Data presented as the
mean 6 SD.
(TIF)
Figure S4 Proliferation. Representative micrographs of co-
labeling of (A) CD68, (B) CD11b, (C) PDGFR-a,( D) PDGFR-b,
and (E) NG2 with Ki67 at day 5 post-injury in rats treated with
PBS starting 30 minutes after injury. (F) Quantification of
proliferating cells assessed through Ki67-positive area within the
injury site and in spinal segments 7 and 14 mm rostrally and
caudally from the injury 5 days post-injury in rats treated with
either 30 minute delayed PBS or imatinib treatment (imatinib,
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the injury site at day 5 post-injury (imatinib, N=4; PBS, N=4).
Arrows indicate co-labeled cells. Data presented as mean 6 SD:
*P,0.05 and ***P,0.001. Scale bars: (A, B)1 0mm, (C-E)2 0mm.
(TIF)
Figure S5 Macrophage/microglia co-expression with
PDGFR-a. Representative micrographs of CD68 expression with
(A) PDGFR-a and (B) NG2 expression within the injury site at day
7 post-injury. Representative micrographs of CD11b co-localiza-
tion with NG2 at (C) 14 mm caudal and (D) 7 mm caudal to the
injury site and (E) within the injury site. Scale bars: 100 mm.
(TIF)
Figure S6 Scatter plot respresentation of CS56 and NG2
expression. (A) Quantification of CS56 immunoreactivity and
(B) NG2 immunoreactivity within the injury site at day 5 post-
injury (imatinib, N=4; PBS, N=4). Data presented as mean 6
SD.
(TIF)
Figure S7 PDGFR expression patterns. PDGFR expression
at 24 hours post-injury in rats pre-treated with imatinib or PBS 4
hours before injury. (A) Representative micrographs of PDGFR-a
expression in sham operated, PBS, and imatinib treated rats. (B)
Quantification of the area of PDGFR-a immunoreactivity. (C)
Representative micrographs of PDGFR-b expression in sham
operated, PBS, and imatinib treated rats. (D) Quantification of the
area of PDGFR-b immunoreactivity. Imatinib (n=4), PBS (n=4),
Sham (n=1). Data presented as mean 6 SD: *P,0.05, **P,0.01,
and ***P,0.001. Scale bars: 100 mm.
(TIF)
Figure S8 PDGFR co-expression. PDGFR expression in
uninjured and injured mouse and rat spinal cords at day 5 post-
injury. (A) Representative micrographs of PDGFR-a promotor
driven GFP and NeuN/DAPI immunoreactivity in non-injured
mouse spinal cord. (B) Representative micrographs of PDGFR-a/
NeuN/DAPI immunoreactivity in noninjured mouse spinal cord.
(C) Representative micrographs of PDGFR-b/NeuN/DAPI
immunoreactivity in noninjured mouse spinal cord. (D) Repre-
sentative micrographs of PDGFR-a/NeuN/DAPI immunoreac-
tivity in injured rat spinal cord. (E) Representative micrographs of
PDGFR-b/NeuN/DAPI immunoreactivity in injured rat spinal
cord. Scale bars: 10 mm( A-C), 50 mm( D,E).
(TIF)
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